Abbott pioneered the breakthrough MitraClip therapy, which provides unmatched TMVr efficacy.1-4
reaching every heart’s
potential
potential
Patient well-being is at the core of everything we do.
And it’s where our unwavering focus will always
be. Because like you, we’re relentlessly
dedicated to restoring healthy hearts that are
filled with possibilities. And ready to make a
lifetime of cherished memories.
Explore the Abbott Portfolio of
Structural Heart Solutions
Mitral Regurgitation
A condition in which the mitral valve does not close completely during contraction of the left ventricle, causing blood to leak backward into the left atrium.
Please click on one of the hot spots to learn more about our therapy solutions
Aortic Stenosis
A narrowing of the aortic valve, which reduces or blocks blood flow from the left ventricle to the aorta.
Please click on one of the hot spots to learn more about our therapy solutions
Stroke Risk Reduction
Interventions to prevent thrombus formation include percutaneous closure of the left atrial appendage (LAA) and the patent foramen ovale (PFO).
Please click on one of the hot spots to learn more about our therapy solutions
Congenital defects
Congenital heart defects can involve the walls of the heart, the heart valves, and arteries and veins near the heart, disrupting normal blood flow.
Please click on one of the hot spots to learn more about our therapy solutions
Epic Mitral
Mitraclip
Epic Mitral
The Epic Mitral stented tissue valve is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic mitral heart valve.
×MitraClip
MitraClip is a minimally invasive TMVr therapy that delivers a treatment option for patients with mitral regurgitation who would otherwise go untreated.
×Portico
Trifecta GT
Regent
Portico
The Portico TAVI system is a minimally invasive treatment for patients with aortic valve stenosis.
×Trifecta GT
The Trifecta Valve with Glide Technology (GT) is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve.
×Regent
The Regent mechanical heart valve is intended for patients requiring replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic valve.
×Amplatzer Amulet LAA
Amplatzer PFO
Amplatzer Amulet LAA
A percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with nonvalvular atrial fibrillation.
×Amplatzer PFO
Designed for patent foramen ovale (PFO) closure, the Amplatzer PFO occluder significantly lowers the risk of recurrent ischemic stroke.
×Amplatzer Septal Occluder
Amplatzer VSD Occluder
Amplatzer Septal Occluder
A percutaneous transcatheter device for patients requiring atrial septal defect (ASD) closure.
×Amplatzer VSD Occluder
Ventricular septal defects (VSDs) are the most common congenital heart defect, and Amplatzer Muscular and Membranous VSD Occluders provide minimally invasive treatment options.
×
LEADING EXPERIENCE.
LASTING CONFIDENCE.
LASTING CONFIDENCE.
THE LEADING PFO
CLOSURE DEVICE5
CLOSURE DEVICE5
Amplatzer PFO Occluder created the category of PFO occlusion, sustained leadership over decades of use, and was the first device supported by positive PFO trial results.
THINK YOU KNOW PORTICO?
THINK AGAIN.
THINK AGAIN.
Portico is the first fully resheathable, repositionable, and retrievable aortic valve used for transcatheter aortic valve implantation (TAVI).
Every Heart has
a Story
The testimonials relate to accounts of individuals’ responses to treatments. The patients’ accounts are genuine, typical and documented. However, it does not provide any indication, guide, warranty, or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.
Derek: “It’s Life-Changing” to Receive an LAA Occluder
Derek, who had atrial fibrillation and whose left atrial appendage (LAA) contributed to a stroke, was treated with anticoagulants—but they resulted in a cerebral hemorrhage. David Hildick-Smith, MD, noted that Amplatzer LAA occlusion “reduces the risk of stroke very substantially, but it also offers patients a peace of mind [when they otherwise are] unprotected from the risk of stroke.”
Alan: Finally “Getting the Care” He Needed with Amplatzer PFO Occluder
“It’s scary,” said Alan, who had had a stroke due to a patent foramen ovale, and who didn’t know if and when he might have a recurrent stroke. After Amplatzer PFO closure “He’s like a new man,” his wife, Emma, remarked about Alan, who’s back to walking 12 miles a day as a mail carrier. “And I owe everyone a massive thank you,” Alan said.
Jozef: “Finding Just the Right Device” Helped Turn His Life Around
Over time Jozef’s ventricular septal defect (VSD) precipitated endocarditis, which in turn led to heart failure and kidney failure. After receiving the Amplatzer VSD Occluder Jozef, amazed at his symptom improvement and ability to walk long distances again, said “I feel joy deep inside me—inside my heart.”
Gareth: Getting “A Second Life” with Transcatheter Aortic Valve Implantation (TAVI)
“It was so successful in terms of symptom relief, and his recovery was astoundingly quick,” explained Dave Smith, MD, interventional cardiologist who treated Gareth with the Portico valve. “My life is back, and I can do everything now,” said Gareth.
Alessandro: “I Was at the End of My Life” Before Receiving MitraClip
“I couldn’t walk anymore, I couldn’t climb stairs, I couldn’t do anything,” said Alessandro. After receiving MitraClip which eliminated his mitral regurgitation, “I started to feel well, my breathing was good again, and I could return to cutting grass with a scythe—really my life had begun again.”
AP2947148-WBO Rev. A
- Feldman T, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–54) © 2015 by the American College of Cardiology Foundation.
- Kar S, Whitlow P, Pedersen W, et al. Effectiveness of transcatheter reduction of significant mitral regurgitation in high surgical risk patients with MitraClip: final 5-year results of the EVEREST II High Risk Registry presented at ACC 2014; March 29, 2014; Washington, DC.
- Sorajja P, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2016;67(10):1129-1140.
- Ailawadi G. Updated MitraClip outcomes from the STS TVT Registry. On behalf of the TVT Registry. May 5, 2016.
- Data on file at Abbott.